Allena Pharmaceuticals (Allena Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Jun. 14, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Forward Dividend Yield %?

As of today (2024-06-14), the Forward Annual Dividend Yield of Allena Pharmaceuticals is 0.00%.

As of today (2024-06-14), the Trailing Annual Dividend Yield of Allena Pharmaceuticals is 0.00%.

ALNAQ's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

Allena Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Allena Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Allena Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allena Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's Forward Dividend Yield % falls into.

Allena Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Allena Pharmaceuticals (OTCPK:ALNAQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Allena Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Newton Executive Park, Suite 202, Newton, MA, USA, 02462

Website

https://www.allenapharma.com

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Executives

Louis Md Brenner	officer: See Remarks	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick	director	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz	officer: Chief Financial Officer	4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan	officer: Chief Financial Officer	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p.	10 percent owner	C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp	10 percent owner	11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper	director, 10 percent owner	550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper	director, 10 percent owner	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin	director, officer: Chief Executive Officer	C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139